• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Health Research >In vitro Evaluation of Biofield Treatment on Viral Load Against Human Immunodeficiency-1 and Cytomegalo Viruses
【24h】

In vitro Evaluation of Biofield Treatment on Viral Load Against Human Immunodeficiency-1 and Cytomegalo Viruses

机译：生物领域治疗对人免疫缺陷病毒1和巨细胞病毒的病毒载量的体外评价。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Viral load quantification is the amount of particular viral DNA or RNA in a blood samples. It is one of the surrogate biomarker of AIDS. High viral load indicates that the immune system is failed to fight against viruses. The aim of this study was to evaluate the impact of biofield treatment on HIV-1 and HCMV in terms of viral loads as surrogate marker. The viral load assay was performed on stored stock cultures of HIV infected human plasma samples before and after 7 days of biofield treatment using Roche COBAS AMPLICOR analyzer. Viral load (HIV-1 RNA and HCMV DNAaemia) was considered as surrogate marker for assessment of the impact of Mr. Trivedi's biofield treatment in HIV infected stored plasma samples. The viral load quantification of HIV-1 RNA in infected stored plasma samples was significantly reduced by 65% in biofield treated group as compared to control. Additionally, viral load of HCMV DNAaemia in infected stored plasma samples was also reduced by 80% in the biofield treated group as compared to control. Because, children are more prone to HCMV infection and adults are generally liable to suffer from HIV-1 infection. As the biofield treatment has reduced HCMV DNAaemia, it could be beneficial for HIV infected children populations. Altogether, data suggest that biofield treatment has significantly reduced the viral load quantification in HIV-1 and HCMV infected stored plasma samples and could be a suitable alternative treatment strategy for AIDS patients in near future.
机译：病毒载量定量是血液样本中特定病毒DNA或RNA的量。它是艾滋病的替代生物标志物之一。高病毒载量表明免疫系统无法抵抗病毒。这项研究的目的是以病毒载量作为替代指标，评估生物场治疗对HIV-1和HCMV的影响。使用Roche COBAS AMPLICOR分析仪在生物田处理7天之前和之后，对储存的HIV感染的人类血浆样品的原种培养物进行病毒载量测定。病毒载量（HIV-1 RNA和HCMV DNAaemia）被认为是评估Trivedi先生的生物场治疗对感染HIV的血浆样品影响的替代指标。与对照组相比，在生物野处理组中，感染的储存血浆样品中HIV-1 RNA的病毒载量定量显着降低了65％。另外，与对照相比，在生物场治疗组中，感染的储存血浆样品中HCMV DNAaemia的病毒载量也降低了80％。因为，儿童更容易感染HCMV，成年人通常容易感染HIV-1。由于生物领域的治疗减少了HCMV DNA血症，因此对感染HIV的儿童人群可能是有益的。总体而言，数据表明，生物现场治疗已大大降低了HIV-1和HCMV感染的血浆样品中病毒载量的量化，并且可能在不久的将来成为AIDS患者的合适替代治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号